ID

DB00217|APRD00825||

名称

Bethanidine

描述

A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

cas号

55-73-2

唯一标识码

W8S3YM7AUU

状态

solid

组

approved,

指示

For the treatment of hypertension.

药效学

Bethanidine is a guanidinium antihypertensive agent that acts by blocking adrenergic transmission. The precise mode of action is not clear. Although bethanidine may produce adverse effects, they are beneficial in severe hypertension and produce fewer side effects than guanethidine.

作用机制

Bethanidine, a guanidine derivative, is a peripherally acting antiadrenergic agent which primarily acts as an alpha2a adrenergic agonist. Bethanidine effectively decreases blood pressure by suppressing renin secretion or interfering with function of the sympathetic nervous system.

毒性

代谢

吸收

Absorbed rapidly in the gastrointestinal tract following oral administration.

半衰期

9 hours (range 7 to 11 hours)

分类

description:This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
direct-parent:Benzene and substituted derivatives
kingdom:Organic compounds
superclass:Benzenoids
class:Benzene and substituted derivatives
subclass:
alternative-parent:Carboximidamides
alternative-parent:Guanidines
alternative-parent:Hydrocarbon derivatives
alternative-parent:Imines
alternative-parent:Organopnictogen compounds
alternative-parent:Propargyl-type 1,3-dipolar organic compounds
substituent:Aromatic homomonocyclic compound
substituent:Carboximidamide
substituent:Guanidine
substituent:Hydrocarbon derivative
substituent:Imine
substituent:Monocyclic benzene moiety
substituent:Organic 1,3-dipolar compound
substituent:Organic nitrogen compound
substituent:Organonitrogen compound
substituent:Organopnictogen compound
substituent:Propargyl-type 1,3-dipolar organic compound

消除途径

种类

Adrenergic Agents
D018663
Adrenergic Agonists
D000322
Adrenergic alpha-2 Receptor Agonists
D058647
Adrenergic alpha-Agonists
D000316
Agents producing tachycardia

Agents that produce hypertension

Amidines
D000578
Antiadrenergic Agents, Peripherally Acting

Antihypertensive Agents
D000959
Autonomic Agents
D001337
Cardiovascular Agents
D002317
Guanidine Derivatives

Guanidines
D006146
Neurotransmitter Agents
D018377
Peripheral Nervous System Agents
D018373
Sympatholytics
D013565

盐类

DBSALT000194Bethanidine sulfateJ4THI5N7O2114-85-2YTIJUXVIZLYQTB-UHFFFAOYSA-N452.571452.220574232

蛋白质结合

清除

同义词

language:spanish; code:inn; name;Betanidina
language:english; code:inn; name;Betanidine
language:french; code:inn; name;Bétanidine
language:latin; code:inn; name;Betanidinum
language:english; code:usan; name;Bethanidine
language:english; code:; name;N,N'-dimethyl-N''-(phenylmethyl)-guanidine

国际品牌

Esbatal

配送量

产品

混合物

包装者

生产者

generic:否; url:; name;Ah robins co

价格

受影响的生物体

Humans and other mammals

剂量

atc代码

Guanidine derivatives
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
ANTIHYPERTENSIVES
CARDIOVASCULAR SYSTEM

fda标签

化学品安全技术说明书

专利

食物相互作用

药物相互作用

DB00346
Alfuzosin may increase the hypotensive activities of Bethanidine.
DB01143
Bethanidine may increase the hypotensive activities of Amifostine.
DB01119
Diazoxide may increase the hypotensive activities of Bethanidine.
DB00422
Methylphenidate may decrease the antihypertensive activities of Bethanidine.
DB06701
Dexmethylphenidate may decrease the antihypertensive activities of Bethanidine.
DB08935
Bethanidine may increase the hypotensive activities of Obinutuzumab.
DB00806
Pentoxifylline may increase the hypotensive activities of Bethanidine.
DB00073
Bethanidine may increase the hypotensive activities of Rituximab.
DB11720
Bethanidine may decrease the antihypertensive activities of Angiotensin 1-7.
DB01392
Yohimbine may decrease the antihypertensive activities of Bethanidine.
DB02032
Epicaptopril may decrease the antihypertensive activities of Bethanidine.
DB12371
Siponimod may decrease the antihypertensive activities of Bethanidine.
DB01023
Felodipine may decrease the antihypertensive activities of Bethanidine.
DB00177
Valsartan may decrease the antihypertensive activities of Bethanidine.
DB00178
Ramipril may decrease the antihypertensive activities of Bethanidine.
DB00206
Reserpine may decrease the antihypertensive activities of Bethanidine.
DB00214
Torasemide may decrease the antihypertensive activities of Bethanidine.
DB00270
Isradipine may decrease the antihypertensive activities of Bethanidine.
DB00275
Olmesartan may decrease the antihypertensive activities of Bethanidine.
DB00310
Chlorthalidone may decrease the antihypertensive activities of Bethanidine.
DB00325
Nitroprusside may decrease the antihypertensive activities of Bethanidine.
DB00343
Diltiazem may decrease the antihypertensive activities of Bethanidine.
DB00350
Minoxidil may decrease the antihypertensive activities of Bethanidine.
DB00381
Amlodipine may decrease the antihypertensive activities of Bethanidine.
DB00393
Nimodipine may decrease the antihypertensive activities of Bethanidine.
DB00401
Nisoldipine may decrease the antihypertensive activities of Bethanidine.
DB00492
Fosinopril may decrease the antihypertensive activities of Bethanidine.
DB00519
Trandolapril may decrease the antihypertensive activities of Bethanidine.
DB00524
Metolazone may decrease the antihypertensive activities of Bethanidine.
DB00528
Lercanidipine may decrease the antihypertensive activities of Bethanidine.
DB00542
Benazepril may decrease the antihypertensive activities of Bethanidine.
DB00584
Enalapril may decrease the antihypertensive activities of Bethanidine.
DB00633
Dexmedetomidine may decrease the antihypertensive activities of Bethanidine.
DB00657
Mecamylamine may decrease the antihypertensive activities of Bethanidine.
DB00678
Losartan may decrease the antihypertensive activities of Bethanidine.
DB00691
Moexipril may decrease the antihypertensive activities of Bethanidine.
DB00695
Furosemide may decrease the antihypertensive activities of Bethanidine.
DB00700
Eplerenone may decrease the antihypertensive activities of Bethanidine.
DB00708
Sufentanil may decrease the antihypertensive activities of Bethanidine.
DB00722
Lisinopril may decrease the antihypertensive activities of Bethanidine.
DB00727
Nitroglycerin may decrease the antihypertensive activities of Bethanidine.
DB00753
Isoflurane may decrease the antihypertensive activities of Bethanidine.
DB00790
Perindopril may decrease the antihypertensive activities of Bethanidine.
DB00796
Candesartan cilexetil may decrease the antihypertensive activities of Bethanidine.
DB00800
Fenoldopam may decrease the antihypertensive activities of Bethanidine.
DB00818
Propofol may decrease the antihypertensive activities of Bethanidine.
DB00876
Eprosartan may decrease the antihypertensive activities of Bethanidine.
DB00881
Quinapril may decrease the antihypertensive activities of Bethanidine.
DB00899
Remifentanil may decrease the antihypertensive activities of Bethanidine.
DB00966
Telmisartan may decrease the antihypertensive activities of Bethanidine.
DB00968
Methyldopa may decrease the antihypertensive activities of Bethanidine.
DB01018
Guanfacine may decrease the antihypertensive activities of Bethanidine.
DB01029
Irbesartan may decrease the antihypertensive activities of Bethanidine.
DB01054
Nitrendipine may decrease the antihypertensive activities of Bethanidine.
DB01158
Bretylium may decrease the antihypertensive activities of Bethanidine.
DB01159
Halothane may decrease the antihypertensive activities of Bethanidine.
DB01189
Desflurane may decrease the antihypertensive activities of Bethanidine.
DB01197
Captopril may decrease the antihypertensive activities of Bethanidine.
DB01236
Sevoflurane may decrease the antihypertensive activities of Bethanidine.
DB01244
Bepridil may decrease the antihypertensive activities of Bethanidine.
DB01275
Hydralazine may decrease the antihypertensive activities of Bethanidine.
DB01340
Cilazapril may decrease the antihypertensive activities of Bethanidine.
DB04948
Lofexidine may decrease the antihypertensive activities of Bethanidine.
DB05271
Rotigotine may decrease the antihypertensive activities of Bethanidine.
DB06712
Nilvadipine may decrease the antihypertensive activities of Bethanidine.
DB08931
Riociguat may decrease the antihypertensive activities of Bethanidine.
DB08941
Isoxsuprine may decrease the antihypertensive activities of Bethanidine.
DB09026
Aliskiren may decrease the antihypertensive activities of Bethanidine.
DB09235
Efonidipine may decrease the antihypertensive activities of Bethanidine.
DB09236
Lacidipine may decrease the antihypertensive activities of Bethanidine.
DB09242
Moxonidine may decrease the antihypertensive activities of Bethanidine.
DB09477
Enalaprilat may decrease the antihypertensive activities of Bethanidine.
DB11783
Imidapril may decrease the antihypertensive activities of Bethanidine.
DB00945
Acetylsalicylic acid may decrease the antihypertensive activities of Bethanidine.
DB15685
Selpercatinib may decrease the antihypertensive activities of Bethanidine.
DB15965
Naxitamab may decrease the antihypertensive activities of Bethanidine.
DB09237
Bethanidine may decrease the antihypertensive activities of Levamlodipine.
DB00035
The risk or severity of hypertension can be increased when Desmopressin is combined with Bethanidine.
DB00091
The risk or severity of hypertension can be increased when Cyclosporine is combined with Bethanidine.
DB00191
The risk or severity of hypertension can be increased when Phentermine is combined with Bethanidine.
DB00211
The risk or severity of hypertension can be increased when Midodrine is combined with Bethanidine.
DB00216
The risk or severity of hypertension can be increased when Eletriptan is combined with Bethanidine.
DB00221
The risk or severity of hypertension can be increased when Bethanidine is combined with Isoetharine.
DB00289
The risk or severity of hypertension can be increased when Bethanidine is combined with Atomoxetine.
DB00292
The risk or severity of hypertension can be increased when Bethanidine is combined with Etomidate.
DB00315
The risk or severity of hypertension can be increased when Bethanidine is combined with Zolmitriptan.
DB00368
The risk or severity of hypertension can be increased when Bethanidine is combined with Norepinephrine.
DB00388
The risk or severity of hypertension can be increased when Bethanidine is combined with Phenylephrine.
DB00397
The risk or severity of hypertension can be increased when Bethanidine is combined with Phenylpropanolamine.
DB00490
The risk or severity of hypertension can be increased when Bethanidine is combined with Buspirone.
DB00561
The risk or severity of hypertension can be increased when Bethanidine is combined with Doxapram.
DB00572
The risk or severity of hypertension can be increased when Bethanidine is combined with Atropine.
DB00610
The risk or severity of hypertension can be increased when Bethanidine is combined with Metaraminol.
DB00668
The risk or severity of hypertension can be increased when Bethanidine is combined with Epinephrine.
DB00669
The risk or severity of hypertension can be increased when Bethanidine is combined with Sumatriptan.
DB00723
The risk or severity of hypertension can be increased when Bethanidine is combined with Methoxamine.
DB00802
The risk or severity of hypertension can be increased when Bethanidine is combined with Alfentanil.
DB00813
The risk or severity of hypertension can be increased when Bethanidine is combined with Fentanyl.
DB00816
The risk or severity of hypertension can be increased when Bethanidine is combined with Orciprenaline.
DB00830
The risk or severity of hypertension can be increased when Bethanidine is combined with Phenmetrazine.
DB00841
The risk or severity of hypertension can be increased when Bethanidine is combined with Dobutamine.
DB00852
The risk or severity of hypertension can be increased when Bethanidine is combined with Pseudoephedrine.
DB00865
The risk or severity of hypertension can be increased when Bethanidine is combined with Benzphetamine.
DB00867
The risk or severity of hypertension can be increased when Bethanidine is combined with Ritodrine.
DB00871
The risk or severity of hypertension can be increased when Bethanidine is combined with Terbutaline.
DB00901
The risk or severity of hypertension can be increased when Bethanidine is combined with Bitolterol.
DB00918
The risk or severity of hypertension can be increased when Bethanidine is combined with Almotriptan.
DB00935
The risk or severity of hypertension can be increased when Bethanidine is combined with Oxymetazoline.
DB00937
The risk or severity of hypertension can be increased when Bethanidine is combined with Diethylpropion.
DB00938
The risk or severity of hypertension can be increased when Bethanidine is combined with Salmeterol.
DB00952
The risk or severity of hypertension can be increased when Bethanidine is combined with Naratriptan.
DB00953
The risk or severity of hypertension can be increased when Bethanidine is combined with Rizatriptan.
DB00988
The risk or severity of hypertension can be increased when Bethanidine is combined with Dopamine.
DB00998
The risk or severity of hypertension can be increased when Bethanidine is combined with Frovatriptan.
DB01001
The risk or severity of hypertension can be increased when Bethanidine is combined with Salbutamol.
DB01028
The risk or severity of hypertension can be increased when Bethanidine is combined with Methoxyflurane.
DB01064
The risk or severity of hypertension can be increased when Bethanidine is combined with Isoprenaline.
DB01102
The risk or severity of hypertension can be increased when Bethanidine is combined with Arbutamine.
DB01126
The risk or severity of hypertension can be increased when Bethanidine is combined with Dutasteride.
DB01216
The risk or severity of hypertension can be increased when Bethanidine is combined with Finasteride.
DB01255
The risk or severity of hypertension can be increased when Bethanidine is combined with Lisdexamfetamine.
DB01274
The risk or severity of hypertension can be increased when Bethanidine is combined with Arformoterol.
DB01288
The risk or severity of hypertension can be increased when Bethanidine is combined with Fenoterol.
DB01291
The risk or severity of hypertension can be increased when Bethanidine is combined with Pirbuterol.
DB01363
The risk or severity of hypertension can be increased when Bethanidine is combined with Ephedra sinica root.
DB01364
The risk or severity of hypertension can be increased when Bethanidine is combined with Ephedrine.
DB01365
The risk or severity of hypertension can be increased when Bethanidine is combined with Mephentermine.
DB01366
The risk or severity of hypertension can be increased when Bethanidine is combined with Procaterol.
DB01407
The risk or severity of hypertension can be increased when Bethanidine is combined with Clenbuterol.
DB01408
The risk or severity of hypertension can be increased when Bethanidine is combined with Bambuterol.
DB01442
The risk or severity of hypertension can be increased when Bethanidine is combined with MMDA.
DB01454
The risk or severity of hypertension can be increased when Bethanidine is combined with Midomafetamine.
DB01467
The risk or severity of hypertension can be increased when Bethanidine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
DB01472
The risk or severity of hypertension can be increased when Bethanidine is combined with 4-Methoxyamphetamine.
DB01484
The risk or severity of hypertension can be increased when Bethanidine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB01509
The risk or severity of hypertension can be increased when Bethanidine is combined with Tenamfetamine.
DB01556
The risk or severity of hypertension can be increased when Bethanidine is combined with Chlorphentermine.
DB01576
The risk or severity of hypertension can be increased when Bethanidine is combined with Dextroamphetamine.
DB01577
The risk or severity of hypertension can be increased when Bethanidine is combined with Metamfetamine.
DB01579
The risk or severity of hypertension can be increased when Bethanidine is combined with Phendimetrazine.
DB01591
The risk or severity of hypertension can be increased when Bethanidine is combined with Solifenacin.
DB04581
The risk or severity of hypertension can be increased when Bethanidine is combined with 1-benzylimidazole.
DB04908
The risk or severity of hypertension can be increased when Bethanidine is combined with Flibanserin.
DB05039
The risk or severity of hypertension can be increased when Bethanidine is combined with Indacaterol.
DB05395
The risk or severity of hypertension can be increased when Bethanidine is combined with Amibegron.
DB05562
The risk or severity of hypertension can be increased when Bethanidine is combined with Naluzotan.
DB06016
The risk or severity of hypertension can be increased when Bethanidine is combined with Cariprazine.
DB06152
The risk or severity of hypertension can be increased when Bethanidine is combined with Nylidrin.
DB06190
The risk or severity of hypertension can be increased when Bethanidine is combined with Solabegron.
DB06262
The risk or severity of hypertension can be increased when Bethanidine is combined with Droxidopa.
DB06678
The risk or severity of hypertension can be increased when Bethanidine is combined with Esmirtazapine.
DB06684
The risk or severity of hypertension can be increased when Bethanidine is combined with Vilazodone.
DB06690
The risk or severity of hypertension can be increased when Bethanidine is combined with Nitrous oxide.
DB06694
The risk or severity of hypertension can be increased when Bethanidine is combined with Xylometazoline.
DB06706
The risk or severity of hypertension can be increased when Bethanidine is combined with Isometheptene.
DB06707
The risk or severity of hypertension can be increased when Bethanidine is combined with Levonordefrin.
DB06711
The risk or severity of hypertension can be increased when Bethanidine is combined with Naphazoline.
DB06763
The risk or severity of hypertension can be increased when Bethanidine is combined with Saralasin.
DB06764
The risk or severity of hypertension can be increased when Bethanidine is combined with Tetryzoline.
DB08810
The risk or severity of hypertension can be increased when Bethanidine is combined with Cinitapride.
DB08815
The risk or severity of hypertension can be increased when Bethanidine is combined with Lurasidone.
DB08841
The risk or severity of hypertension can be increased when Bethanidine is combined with Tyramine.
DB08893
The risk or severity of hypertension can be increased when Bethanidine is combined with Mirabegron.
DB08925
The risk or severity of hypertension can be increased when Bethanidine is combined with Adrafinil.
DB08954
The risk or severity of hypertension can be increased when Bethanidine is combined with Ifenprodil.
DB08957
The risk or severity of hypertension can be increased when Bethanidine is combined with Hexoprenaline.
DB08985
The risk or severity of hypertension can be increased when Bethanidine is combined with Etilefrine.
DB09061
The risk or severity of hypertension can be increased when Bethanidine is combined with Cannabidiol.
DB09068
The risk or severity of hypertension can be increased when Bethanidine is combined with Vortioxetine.
DB09080
The risk or severity of hypertension can be increased when Bethanidine is combined with Olodaterol.
DB09082
The risk or severity of hypertension can be increased when Bethanidine is combined with Vilanterol.
DB09202
The risk or severity of hypertension can be increased when Bethanidine is combined with Cirazoline.
DB09203
The risk or severity of hypertension can be increased when Bethanidine is combined with Synephrine.
DB09205
The risk or severity of hypertension can be increased when Bethanidine is combined with Moxisylyte.
DB09480
The risk or severity of hypertension can be increased when Bethanidine is combined with Iofetamine I-123.
DB11124
The risk or severity of hypertension can be increased when Bethanidine is combined with Racepinephrine.
DB11278
The risk or severity of hypertension can be increased when Bethanidine is combined with DL-Methylephedrine.
DB11373
The risk or severity of hypertension can be increased when Bethanidine is combined with Amitraz.
DB11428
The risk or severity of hypertension can be increased when Bethanidine is combined with Medetomidine.
DB11477
The risk or severity of hypertension can be increased when Bethanidine is combined with Xylazine.
DB11481
The risk or severity of hypertension can be increased when Bethanidine is combined with Atipamezole.
DB11541
The risk or severity of hypertension can be increased when Bethanidine is combined with Ractopamine.
DB11543
The risk or severity of hypertension can be increased when Bethanidine is combined with Romifidine.
DB11556
The risk or severity of hypertension can be increased when Bethanidine is combined with Detomidine.
DB11587
The risk or severity of hypertension can be increased when Bethanidine is combined with Etafedrine.
DB11755
The risk or severity of hypertension can be increased when Bethanidine is combined with Tetrahydrocannabivarin.
DB11871
The risk or severity of hypertension can be increased when Bethanidine is combined with PF-00610355.
DB12080
The risk or severity of hypertension can be increased when Bethanidine is combined with Ritobegron.
DB12100
The risk or severity of hypertension can be increased when Bethanidine is combined with Abediterol.
DB12248
The risk or severity of hypertension can be increased when Bethanidine is combined with Tulobuterol.
DB12313
The risk or severity of hypertension can be increased when Bethanidine is combined with Dopexamine.
DB12361
The risk or severity of hypertension can be increased when Bethanidine is combined with Piclozotan.
DB12551
The risk or severity of hypertension can be increased when Bethanidine is combined with Idazoxan.
DB12779
The risk or severity of hypertension can be increased when Bethanidine is combined with Higenamine.
DB12846
The risk or severity of hypertension can be increased when Bethanidine is combined with Reproterol.
DB12927
The risk or severity of hypertension can be increased when Bethanidine is combined with Theodrenaline.
DB13064
The risk or severity of hypertension can be increased when Bethanidine is combined with Tramazoline.
DB13108
The risk or severity of hypertension can be increased when Bethanidine is combined with Mephedrone.
DB13139
The risk or severity of hypertension can be increased when Bethanidine is combined with Levosalbutamol.
DB13251
The risk or severity of hypertension can be increased when Bethanidine is combined with Octopamine.
DB13323
The risk or severity of hypertension can be increased when Bethanidine is combined with Trichloroethylene.
DB13341
The risk or severity of hypertension can be increased when Bethanidine is combined with Fenozolone.
DB13378
The risk or severity of hypertension can be increased when Bethanidine is combined with Norfenefrine.
DB13398
The risk or severity of hypertension can be increased when Bethanidine is combined with Oxyfedrine.
DB13453
The risk or severity of hypertension can be increased when Bethanidine is combined with Xenon.
DB13510
The risk or severity of hypertension can be increased when Bethanidine is combined with Buflomedil.
DB13559
The risk or severity of hypertension can be increased when Bethanidine is combined with Rimiterol.
DB13598
The risk or severity of hypertension can be increased when Bethanidine is combined with Diethyl ether.
DB13624
The risk or severity of hypertension can be increased when Bethanidine is combined with Methoxyphenamine.
DB13692
The risk or severity of hypertension can be increased when Bethanidine is combined with Tretoquinol.
DB13703
The risk or severity of hypertension can be increased when Bethanidine is combined with Gepefrine.
DB13777
The risk or severity of hypertension can be increased when Bethanidine is combined with Prenalterol.
DB13781
The risk or severity of hypertension can be increased when Bethanidine is combined with Xamoterol.
DB13852
The risk or severity of hypertension can be increased when Bethanidine is combined with Mefenorex.
DB13917
The risk or severity of hypertension can be increased when Bethanidine is combined with Deoxyepinephrine.
DB13940
The risk or severity of hypertension can be increased when Bethanidine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB14010
The risk or severity of hypertension can be increased when Bethanidine is combined with 5-methoxy-N,N-dimethyltryptamine.
DB14231
The risk or severity of hypertension can be increased when Bethanidine is combined with Quinoline Yellow WS.
DB00895
Bethanidine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
DB00070
The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Bethanidine.
DB06205
The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Bethanidine.
DB14740
The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bethanidine.
DB00421
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Spironolactone.
DB06148
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mianserin.
DB00370
Mirtazapine may decrease the antihypertensive activities of Bethanidine.
DB09282
Molsidomine may increase the hypotensive activities of Bethanidine.
DB00212
Remikiren may increase the hypotensive activities of Bethanidine.
DB00226
Bethanidine may increase the hypotensive activities of Guanadrel.
DB00287
Bethanidine may increase the hypotensive activities of Travoprost.
DB00521
Bethanidine may increase the hypotensive activities of Carteolol.
DB00559
Bethanidine may increase the hypotensive activities of Bosentan.
DB00616
Bethanidine may increase the hypotensive activities of Candoxatril.
DB00629
Bethanidine may increase the hypotensive activities of Guanabenz.
DB00765
Bethanidine may increase the hypotensive activities of Metyrosine.
DB00785
Bethanidine may increase the hypotensive activities of Cryptenamine.
DB00869
Bethanidine may increase the hypotensive activities of Dorzolamide.
DB00886
Bethanidine may increase the hypotensive activities of Omapatrilat.
DB00905
Bethanidine may increase the hypotensive activities of Bimatoprost.
DB01089
Bethanidine may increase the hypotensive activities of Deserpidine.
DB01090
Bethanidine may increase the hypotensive activities of Pentolinium.
DB01116
Bethanidine may increase the hypotensive activities of Trimethaphan.
DB01170
Bethanidine may increase the hypotensive activities of Guanethidine.
DB01180
Bethanidine may increase the hypotensive activities of Rescinnamine.
DB01214
Bethanidine may increase the hypotensive activities of Metipranolol.
DB01347
Bethanidine may increase the hypotensive activities of Saprisartan.
DB01348
Bethanidine may increase the hypotensive activities of Spirapril.
DB01388
Bethanidine may increase the hypotensive activities of Mibefradil.
DB04831
Bethanidine may increase the hypotensive activities of Tienilic acid.
DB04840
Bethanidine may increase the hypotensive activities of Debrisoquine.
DB06268
Bethanidine may increase the hypotensive activities of Sitaxentan.
DB06403
Bethanidine may increase the hypotensive activities of Ambrisentan.
DB06445
Bethanidine may increase the hypotensive activities of Diethylnorspermine.
DB06762
Bethanidine may increase the hypotensive activities of Pinacidil.
DB06826
Bethanidine may increase the hypotensive activities of Unoprostone.
DB07767
Bethanidine may increase the hypotensive activities of Ferulic acid.
DB08836
Bethanidine may increase the hypotensive activities of Temocapril.
DB08932
Bethanidine may increase the hypotensive activities of Macitentan.
DB08960
Bethanidine may increase the hypotensive activities of Hexamethonium.
DB09220
Bethanidine may increase the hypotensive activities of Nicorandil.
DB09238
Bethanidine may increase the hypotensive activities of Manidipine.
DB09363
Bethanidine may increase the hypotensive activities of Rauwolfia serpentina root.
DB11362
Bethanidine may increase the hypotensive activities of Selexipag.
DB11738
Bethanidine may increase the hypotensive activities of Rilmenidine.
DB12054
Bethanidine may increase the hypotensive activities of BQ-123.
DB12092
Bethanidine may increase the hypotensive activities of Naftopidil.
DB12093
Bethanidine may increase the hypotensive activities of Tetrahydropalmatine.
DB12465
Bethanidine may increase the hypotensive activities of Ketanserin.
DB12766
Bethanidine may increase the hypotensive activities of Cicletanine.
DB12945
Bethanidine may increase the hypotensive activities of Dihydralazine.
DB13166
Bethanidine may increase the hypotensive activities of Zofenopril.
DB13211
Bethanidine may increase the hypotensive activities of Guanoxan.
DB13312
Bethanidine may increase the hypotensive activities of Delapril.
DB13374
Bethanidine may increase the hypotensive activities of Vincamine.
DB13400
Bethanidine may increase the hypotensive activities of Linsidomine.
DB13410
Bethanidine may increase the hypotensive activities of Guanoxabenz.
DB13429
Bethanidine may increase the hypotensive activities of Tolonidine.
DB13435
Bethanidine may increase the hypotensive activities of Endralazine.
DB13452
Bethanidine may increase the hypotensive activities of Cadralazine.
DB13575
Bethanidine may increase the hypotensive activities of Bietaserpine.
DB13604
Bethanidine may increase the hypotensive activities of Guanazodine.
DB13631
Bethanidine may increase the hypotensive activities of Methoserpidine.
DB13779
Bethanidine may increase the hypotensive activities of Guanoclor.
DB13801
Bethanidine may increase the hypotensive activities of Muzolimine.
DB13803
Bethanidine may increase the hypotensive activities of Xipamide.
DB13919
Bethanidine may increase the hypotensive activities of Candesartan.
DB14068
Bethanidine may increase the hypotensive activities of Dexniguldipine.
DB14094
Bethanidine may increase the hypotensive activities of Tocopherylquinone.
DB14125
Bethanidine may increase the hypotensive activities of Benazeprilat.
DB14207
Bethanidine may increase the hypotensive activities of Fosinoprilat.
DB14208
Bethanidine may increase the hypotensive activities of Ramiprilat.
DB14213
Bethanidine may increase the hypotensive activities of Perindoprilat.
DB14217
Bethanidine may increase the hypotensive activities of Quinaprilat.
DB00484
Brimonidine may increase the antihypertensive activities of Bethanidine.
DB00203
Sildenafil may increase the antihypertensive activities of Bethanidine.
DB00235
Milrinone may increase the antihypertensive activities of Bethanidine.
DB00820
Tadalafil may increase the antihypertensive activities of Bethanidine.
DB00862
Vardenafil may increase the antihypertensive activities of Bethanidine.
DB00975
Dipyridamole may increase the antihypertensive activities of Bethanidine.
DB05266
Ibudilast may increase the antihypertensive activities of Bethanidine.
DB06237
Avanafil may increase the antihypertensive activities of Bethanidine.
DB06267
Udenafil may increase the antihypertensive activities of Bethanidine.
DB09273
Doxofylline may increase the antihypertensive activities of Bethanidine.
DB11792
Mirodenafil may increase the antihypertensive activities of Bethanidine.
DB12010
Fostamatinib may increase the antihypertensive activities of Bethanidine.
DB00247
Methysergide may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00248
Cabergoline may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00320
Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00353
Methylergometrine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00589
Lisuride may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00696
Ergotamine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00699
Nicergoline may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB01049
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB01186
Pergolide may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB01200
Bromocriptine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB01253
Ergometrine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB04829
Lysergic acid diethylamide may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB11273
Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB13345
Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB13385
Dihydroergocryptine may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB13399
Terguride may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB13520
Metergoline may increase the hypertensive and vasoconstricting activities of Bethanidine.
DB00285
Venlafaxine may increase the tachycardic activities of Bethanidine.
DB00476
Duloxetine may increase the tachycardic activities of Bethanidine.
DB01105
Sibutramine may increase the tachycardic activities of Bethanidine.
DB04896
Milnacipran may increase the tachycardic activities of Bethanidine.
DB06700
Desvenlafaxine may increase the tachycardic activities of Bethanidine.
DB08918
Levomilnacipran may increase the tachycardic activities of Bethanidine.
DB00334
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Olanzapine.
DB00363
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Clozapine.
DB00420
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Promazine.
DB00450
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Droperidol.
DB00477
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Chlorpromazine.
DB00590
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Doxazosin.
DB00622
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nicardipine.
DB00656
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Trazodone.
DB00661
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Verapamil.
DB00679
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Thioridazine.
DB00692
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Phentolamine.
DB00706
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tamsulosin.
DB00734
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Risperidone.
DB00777
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Propiomazine.
DB00797
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tolazoline.
DB00831
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Trifluoperazine.
DB00875
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Flupentixol.
DB00908
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Quinidine.
DB00925
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Phenoxybenzamine.
DB01149
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nefazodone.
DB01162
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Terazosin.
DB01267
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Paliperidone.
DB01403
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Methotrimeprazine.
DB01608
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Periciazine.
DB01614
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Acepromazine.
DB01622
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Thioproperazine.
DB01624
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Zuclopenthixol.
DB04855
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Dronedarone.
DB04946
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Iloperidone.
DB06153
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Pizotifen.
DB06207
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Silodosin.
DB06216
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Asenapine.
DB08950
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Indoramin.
DB09128
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Brexpiprazole.
DB09206
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Trimazosin.
DB09239
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Niguldipine.
DB12230
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bunazosin.
DB12278
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Propiverine.
DB12661
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Urapidil.
DB00321
The risk or severity of hypertension can be increased when Amitriptyline is combined with Bethanidine.
DB00458
The risk or severity of hypertension can be increased when Imipramine is combined with Bethanidine.
DB00540
The risk or severity of hypertension can be increased when Nortriptyline is combined with Bethanidine.
DB00543
The risk or severity of hypertension can be increased when Amoxapine is combined with Bethanidine.
DB00726
The risk or severity of hypertension can be increased when Trimipramine is combined with Bethanidine.
DB01142
The risk or severity of hypertension can be increased when Doxepin is combined with Bethanidine.
DB00374
Treprostinil may increase the hypotensive activities of Bethanidine.
DB01088
Iloprost may increase the hypotensive activities of Bethanidine.
DB01240
Epoprostenol may increase the hypotensive activities of Bethanidine.
DB00468
Quinine may increase the hypotensive activities of Bethanidine.
DB14337
Salvia miltiorrhiza root may increase the hypotensive activities of Bethanidine.
DB06704
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Bethanidine.
DB00344
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Protriptyline.
DB01151
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Desipramine.
DB01242
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Clomipramine.
DB04836
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Amineptine.
DB08996
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Dimetacrine.
DB09016
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Butriptyline.
DB09167
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Dosulepin.
DB09289
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tianeptine.
DB09307
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Oxaprotiline.
DB12930
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Opipramol.
DB13114
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Amitriptylinoxide.
DB13225
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Dibenzepin.
DB13246
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Quinupramine.
DB13384
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Melitracen.
DB13411
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Lofepramine.
DB13496
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Iprindole.
DB13782
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Imipramine oxide.
DB00182
Amphetamine may increase the hypotensive activities of Bethanidine.
DB00601
Linezolid may increase the hypotensive activities of Bethanidine.
DB00614
Furazolidone may increase the hypotensive activities of Bethanidine.
DB00721
Procaine may increase the hypotensive activities of Bethanidine.
DB00752
Tranylcypromine may increase the hypotensive activities of Bethanidine.
DB00780
Phenelzine may increase the hypotensive activities of Bethanidine.
DB00805
Minaprine may increase the hypotensive activities of Bethanidine.
DB01037
Selegiline may increase the hypotensive activities of Bethanidine.
DB01168
Procarbazine may increase the hypotensive activities of Bethanidine.
DB01171
Moclobemide may increase the hypotensive activities of Bethanidine.
DB01247
Isocarboxazid may increase the hypotensive activities of Bethanidine.
DB01367
Rasagiline may increase the hypotensive activities of Bethanidine.
DB01626
Pargyline may increase the hypotensive activities of Bethanidine.
DB04017
Clorgiline may increase the hypotensive activities of Bethanidine.
DB04818
Iproniazid may increase the hypotensive activities of Bethanidine.
DB04820
Nialamide may increase the hypotensive activities of Bethanidine.
DB06654
Safinamide may increase the hypotensive activities of Bethanidine.
DB08550
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Bethanidine.
DB09241
Methylene blue may increase the hypotensive activities of Bethanidine.
DB09243
Hydracarbazine may increase the hypotensive activities of Bethanidine.
DB09244
Pirlindole may increase the hypotensive activities of Bethanidine.
DB09245
Toloxatone may increase the hypotensive activities of Bethanidine.
DB09246
Benmoxin may increase the hypotensive activities of Bethanidine.
DB09248
Mebanazine may increase the hypotensive activities of Bethanidine.
DB09249
Octamoxin may increase the hypotensive activities of Bethanidine.
DB09250
Pheniprazine may increase the hypotensive activities of Bethanidine.
DB09251
Phenoxypropazine may increase the hypotensive activities of Bethanidine.
DB09252
Pivhydrazine may increase the hypotensive activities of Bethanidine.
DB09253
Safrazine may increase the hypotensive activities of Bethanidine.
DB09254
Caroxazone may increase the hypotensive activities of Bethanidine.
DB13875
Harmaline may increase the hypotensive activities of Bethanidine.
DB13876
Brofaromine may increase the hypotensive activities of Bethanidine.
DB00159
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Icosapent.
DB00244
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mesalazine.
DB00328
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Indomethacin.
DB00461
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nabumetone.
DB00465
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Ketorolac.
DB00469
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tenoxicam.
DB00482
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Celecoxib.
DB00500
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tolmetin.
DB00533
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Rofecoxib.
DB00554
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Piroxicam.
DB00573
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Fenoprofen.
DB00580
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Valdecoxib.
DB00586
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Diclofenac.
DB00605
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Sulindac.
DB00712
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Flurbiprofen.
DB00749
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Etodolac.
DB00784
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mefenamic acid.
DB00788
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Naproxen.
DB00795
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Sulfasalazine.
DB00812
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Phenylbutazone.
DB00814
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Meloxicam.
DB00821
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Carprofen.
DB00861
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Diflunisal.
DB00936
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Salicylic acid.
DB00939
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Meclofenamic acid.
DB00991
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Oxaprozin.
DB01009
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Ketoprofen.
DB01014
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Balsalazide.
DB01050
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Ibuprofen.
DB01250
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Olsalazine.
DB01283
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Lumiracoxib.
DB01397
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Magnesium salicylate.
DB01399
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Salsalate.
DB01401
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Choline magnesium trisalicylate.
DB01419
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Antrafenine.
DB01424
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Aminophenazone.
DB01435
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Antipyrine.
DB01600
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tiaprofenic acid.
DB01628
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Etoricoxib.
DB02224
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Taxifolin.
DB03585
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Oxyphenbutazone.
DB04725
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Licofelone.
DB04743
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nimesulide.
DB04812
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Benoxaprofen.
DB04817
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Metamizole.
DB04828
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Zomepirac.
DB05095
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Cimicoxib.
DB06725
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Lornoxicam.
DB06736
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Aceclofenac.
DB06737
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Zaltoprofen.
DB07402
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Azapropazone.
DB08439
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Parecoxib.
DB08797
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Salicylamide.
DB08940
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Kebuzone.
DB08942
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Isoxicam.
DB08951
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Indoprofen.
DB08955
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Ibuproxam.
DB08976
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Floctafenine.
DB08981
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Fenbufen.
DB08984
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Etofenamate.
DB08991
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Epirizole.
DB09084
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Benzydamine.
DB09213
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Dexibuprofen.
DB09214
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Dexketoprofen.
DB09215
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Droxicam.
DB09216
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tolfenamic acid.
DB09217
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Firocoxib.
DB09218
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Clonixin.
DB09285
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Morniflumate.
DB09288
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Propacetamol.
DB09295
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Talniflumate.
DB11455
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Robenacoxib.
DB11466
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tepoxalin.
DB11518
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Flunixin.
DB12399
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Polmacoxib.
DB12445
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nitroaspirin.
DB12545
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Indobufen.
DB12610
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Ebselen.
DB13001
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tinoridine.
DB13167
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Alclofenac.
DB13217
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Fentiazac.
DB13232
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Suxibuzone.
DB13286
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bumadizone.
DB13314
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Alminoprofen.
DB13371
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Difenpiramide.
DB13407
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nifenazone.
DB13432
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Lonazolac.
DB13481
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tenidap.
DB13524
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Propyphenazone.
DB13527
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Proglumetacin.
DB13538
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Guacetisal.
DB13544
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Ethenzamide.
DB13612
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Carbaspirin calcium.
DB13629
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mofebutazone.
DB13649
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Proquazone.
DB13657
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Benorilate.
DB13722
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Pirprofen.
DB13783
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Acemetacin.
DB13860
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Imidazole salicylate.
DB14059
The therapeutic efficacy of Bethanidine can be decreased when used in combination with SC-236.
DB14060
The therapeutic efficacy of Bethanidine can be decreased when used in combination with NS-398.
DB14938
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Flurbiprofen axetil.
DB09212
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Loxoprofen.
DB09227
Bethanidine may increase the antihypertensive activities of Barnidipine.
DB00187
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Esmolol.
DB00195
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Betaxolol.
DB00264
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Metoprolol.
DB00335
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Atenolol.
DB00373
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Timolol.
DB00489
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Sotalol.
DB00571
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Propranolol.
DB00598
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Labetalol.
DB00612
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bisoprolol.
DB00866
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Alprenolol.
DB00960
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Pindolol.
DB01136
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Carvedilol.
DB01182
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Propafenone.
DB01193
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Acebutolol.
DB01203
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nadolol.
DB01295
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bevantolol.
DB01297
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Practolol.
DB01359
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Penbutolol.
DB01580
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Oxprenolol.
DB03322
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Dexpropranolol.
DB04846
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Celiprolol.
DB04861
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nebivolol.
DB06726
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bufuralol.
DB08807
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bopindolol.
DB08808
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bupranolol.
DB08952
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Indenolol.
DB09204
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Arotinolol.
DB09351
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Levobetaxolol.
DB11770
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Talinolol.
DB11785
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Anisodamine.
DB12752
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Bucindolol.
DB13443
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Esatenolol.
DB13508
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Cloranolol.
DB13530
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mepindolol.
DB13757
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Epanolol.
DB13775
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Tertatolol.
DB12212
The therapeutic efficacy of Landiolol can be decreased when used in combination with Bethanidine.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Bethanidine.
DB00392
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Profenamine.
DB12057
The therapeutic efficacy of Bethanidine can be decreased when used in combination with ORM-12741.
DB00184
The risk or severity of Tachycardia can be increased when Nicotine is combined with Bethanidine.
DB00193
The risk or severity of Tachycardia can be increased when Tramadol is combined with Bethanidine.
DB00209
The risk or severity of Tachycardia can be increased when Trospium is combined with Bethanidine.
DB00219
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Oxyphenonium.
DB00245
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Benzatropine.
DB00280
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Disopyramide.
DB00332
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Ipratropium.
DB00340
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Metixene.
DB00354
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Buclizine.
DB00366
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Doxylamine.
DB00376
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Trihexyphenidyl.
DB00383
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Oxyphencyclimine.
DB00387
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Procyclidine.
DB00424
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Hyoscyamine.
DB00434
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Cyproheptadine.
DB00462
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Methscopolamine bromide.
DB00470
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Dronabinol.
DB00483
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Gallamine triethiodide.
DB00496
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Darifenacin.
DB00505
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Tridihexethyl.
DB00508
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Triflupromazine.
DB00517
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Anisotropine methylbromide.
DB00555
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Lamotrigine.
DB00640
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Adenosine.
DB00670
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Pirenzepine.
DB00715
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Paroxetine.
DB00725
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Homatropine methylbromide.
DB00728
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Rocuronium.
DB00747
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Scopolamine.
DB00767
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Benzquinamide.
DB00771
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Clidinium.
DB00782
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Propantheline.
DB00804
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Dicyclomine.
DB00810
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Biperiden.
DB00835
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Brompheniramine.
DB00907
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Cocaine.
DB00934
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Maprotiline.
DB00940
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Methantheline.
DB00942
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Cycrimine.
DB00986
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Glycopyrronium.
DB01036
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Tolterodine.
DB01062
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Oxybutynin.
DB01069
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Promethazine.
DB01075
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Diphenhydramine.
DB01148
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Flavoxate.
DB01166
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Cilostazol.
DB01173
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Orphenadrine.
DB01221
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Ketamine.
DB01226
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Mivacurium.
DB01231
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Diphenidol.
DB01239
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Chlorprothixene.
DB01336
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Metocurine.
DB01337
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Pancuronium.
DB01338
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Pipecuronium.
DB01409
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Tiotropium.
DB01625
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Isopropamide.
DB04834
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Rapacuronium.
DB04843
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Mepenzolate.
DB05077
The risk or severity of Tachycardia can be increased when Bethanidine is combined with SLV319.
DB06155
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Rimonabant.
DB06702
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Fesoterodine.
DB06787
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Hexocyclium.
DB06814
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Protokylol.
DB08801
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Dimetindene.
DB08897
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Aclidinium.
DB08997
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Dexetimide.
DB09023
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Benactyzine.
DB09076
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Umeclidinium.
DB09089
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Trimebutine.
DB09262
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Imidafenacin.
DB09300
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Butylscopolamine.
DB11235
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Thonzylamine.
DB11315
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Methscopolamine.
DB11903
The risk or severity of Tachycardia can be increased when Bethanidine is combined with GW842166.
DB12086
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Oxitropium.
DB12193
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Ajulemic acid.
DB12554
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Mebeverine.
DB12649
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Ibipinabant.
DB13070
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Surinabant.
DB13252
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Tropatepine.
DB13254
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Prifinium.
DB13351
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Piperidolate.
DB13369
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Benzilone.
DB13380
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Difemerine.
DB13413
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Phenglutarimide.
DB13448
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Mazaticol.
DB13468
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Etybenzatropine.
DB13500
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Otilonium.
DB13505
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Emepronium.
DB13507
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Poldine.
DB13542
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Bevonium.
DB13581
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Rociverine.
DB13619
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Bornaprine.
DB13636
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Etanautine.
DB13666
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Tiemonium iodide.
DB13678
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Dihexyverine.
DB13695
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Penthienate.
DB13720
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Diphemanil.
DB13738
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Camylofin.
DB13759
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Fenpiverinium.
DB13769
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Emetonium iodide.
DB13844
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Pipenzolate.
DB13850
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Timepidium.
DB13950
The risk or severity of Tachycardia can be increased when Bethanidine is combined with WIN 55212-2.
DB14009
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Medical Cannabis.
DB14011
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Nabiximols.
DB14043
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Palmidrol.
DB00486
The risk or severity of Tachycardia can be increased when Nabilone is combined with Bethanidine.
DB00261
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Anagrelide.
DB09007
The risk or severity of Tachycardia can be increased when Bethanidine is combined with Chlorphenoxamine.
DB00190
The risk or severity of hypotension can be increased when Carbidopa is combined with Bethanidine.
DB11823
The risk or severity of hypertension can be increased when Esketamine is combined with Bethanidine.
DB14754
The risk or severity of hypertension can be increased when Solriamfetol is combined with Bethanidine.
DB00457
The risk or severity of hypotension can be increased when Prazosin is combined with Bethanidine.
DB13946
Testosterone undecanoate may increase the hypertensive activities of Bethanidine.
DB00041
Aldesleukin may increase the hypotensive activities of Bethanidine.
DB00086
Streptokinase may increase the hypotensive activities of Bethanidine.
DB00268
Ropinirole may increase the hypotensive activities of Bethanidine.
DB00295
Morphine may increase the hypotensive activities of Bethanidine.
DB00296
Ropivacaine may increase the hypotensive activities of Bethanidine.
DB00297
Bupivacaine may increase the hypotensive activities of Bethanidine.
DB00323
Tolcapone may increase the hypotensive activities of Bethanidine.
DB00384
Triamterene may increase the hypotensive activities of Bethanidine.
DB00413
Pramipexole may increase the hypotensive activities of Bethanidine.
DB00435
Nitric Oxide may increase the hypotensive activities of Bethanidine.
DB00594
Amiloride may increase the hypotensive activities of Bethanidine.
DB00599
Thiopental may increase the hypotensive activities of Bethanidine.
DB00631
Clofarabine may increase the hypotensive activities of Bethanidine.
DB00681
Amphotericin B may increase the hypotensive activities of Bethanidine.
DB00703
Methazolamide may increase the hypotensive activities of Bethanidine.
DB00714
Apomorphine may increase the hypotensive activities of Bethanidine.
DB00742
Mannitol may increase the hypotensive activities of Bethanidine.
DB00755
Tretinoin may increase the hypotensive activities of Bethanidine.
DB00872
Conivaptan may increase the hypotensive activities of Bethanidine.
DB00883
Isosorbide dinitrate may increase the hypotensive activities of Bethanidine.
DB00887
Bumetanide may increase the hypotensive activities of Bethanidine.
DB00903
Etacrynic acid may increase the hypotensive activities of Bethanidine.
DB00922
Levosimendan may increase the hypotensive activities of Bethanidine.
DB01002
Levobupivacaine may increase the hypotensive activities of Bethanidine.
DB01020
Isosorbide mononitrate may increase the hypotensive activities of Bethanidine.
DB01041
Thalidomide may increase the hypotensive activities of Bethanidine.
DB01113
Papaverine may increase the hypotensive activities of Bethanidine.
DB01118
Amiodarone may increase the hypotensive activities of Bethanidine.
DB01144
Diclofenamide may increase the hypotensive activities of Bethanidine.
DB01169
Arsenic trioxide may increase the hypotensive activities of Bethanidine.
DB01229
Paclitaxel may increase the hypotensive activities of Bethanidine.
DB01235
Levodopa may increase the hypotensive activities of Bethanidine.
DB01282
Carbetocin may increase the hypotensive activities of Bethanidine.
DB01612
Amyl Nitrite may increase the hypotensive activities of Bethanidine.
DB04899
Nesiritide may increase the hypotensive activities of Bethanidine.
DB04920
Clevidipine may increase the hypotensive activities of Bethanidine.
DB06292
Dapagliflozin may increase the hypotensive activities of Bethanidine.
DB08822
Azilsartan medoxomil may increase the hypotensive activities of Bethanidine.
DB08907
Canagliflozin may increase the hypotensive activities of Bethanidine.
DB09038
Empagliflozin may increase the hypotensive activities of Bethanidine.
DB09077
Dinutuximab may increase the hypotensive activities of Bethanidine.
DB09112
Nitrous acid may increase the hypotensive activities of Bethanidine.
DB09232
Cilnidipine may increase the hypotensive activities of Bethanidine.
DB09279
Fimasartan may increase the hypotensive activities of Bethanidine.
DB09286
Pipamperone may increase the hypotensive activities of Bethanidine.
DB09292
Sacubitril may increase the hypotensive activities of Bethanidine.
DB01115
Nifedipine may increase the hypotensive activities of Bethanidine.
DB00697
The risk or severity of adverse effects can be increased when Tizanidine is combined with Bethanidine.
DB01238
The risk or severity of hypotension can be increased when Aripiprazole is combined with Bethanidine.
DB14185
The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Bethanidine.
DB00575
The risk or severity of hypotension can be increased when Clonidine is combined with Bethanidine.
DB01224
Quetiapine may increase the hypotensive activities of Bethanidine.
DB00983
Bethanidine may increase the sympathomimetic activities of Formoterol.
DB00246
Ziprasidone may increase the antihypertensive activities of Bethanidine.
DB00606
The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Bethanidine.
DB01021
The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Bethanidine.
DB01324
The therapeutic efficacy of Polythiazide can be increased when used in combination with Bethanidine.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Bethanidine.
DB00232
The therapeutic efficacy of Bethanidine can be increased when used in combination with Methyclothiazide.
DB00436
The therapeutic efficacy of Bethanidine can be increased when used in combination with Bendroflumethiazide.
DB00774
The therapeutic efficacy of Bethanidine can be increased when used in combination with Hydroflumethiazide.
DB00880
The therapeutic efficacy of Bethanidine can be increased when used in combination with Chlorothiazide.
DB00999
The therapeutic efficacy of Bethanidine can be increased when used in combination with Hydrochlorothiazide.
DB00562
The therapeutic efficacy of Bethanidine can be increased when used in combination with Benzthiazide.
DB13430
The therapeutic efficacy of Bethanidine can be increased when used in combination with Mebutizide.
DB00808
The therapeutic efficacy of Bethanidine can be increased when used in combination with Indapamide.

序列

实验性质

Melting Point
196 °C
PhysProp
logP
0.49

外部标识符

resource：ChEBI
identifier：37937
resource：PubChem Compound
identifier：2368
resource：PubChem Substance
identifier：46507605
resource：KEGG Drug
identifier：D01603
resource：ChemSpider
identifier：2278
resource：PharmGKB
identifier：PA164743235
resource：Therapeutic Targets Database
identifier：DAP000047
resource：Wikipedia
identifier：Bethanidine
resource：ChEMBL
identifier：CHEMBL1201260
resource：ZINC
identifier：ZINC000002041046
resource：RxCUI
identifier：1523

外部链接

路径

目标

id:BE0004864
name:Alpha-2 adrenergic receptors
organism:Humans
action:agonist
Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationships between platelet alpha 2-adrenoceptors and sympathetic nerve activity in clinical hypertensive states. J Hypertens. 1990 Dec;8(12):1097-104.
Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationship between platelet alpha 2-adrenoceptors and sympathetic nerve activity in man. Clin Exp Hypertens A. 1989;11 Suppl 1:287-94.
known-action:yes
name:Alpha-2A adrenergic receptor
general-function:Thioesterase binding
specific-function:Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
gene-name:ADRA2A
locus:10q24-q26
cellular-location:Cell membrane
transmembrane-regions:34-59 71-96 107-129 152-172 195-217 375-395 410-429
signal-regions:
theoretical-pi:10.2
molecular-weight:48956.275
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:281GenAtlasADRA2AGenBank Gene DatabaseM23533GenBank Protein Database178196IUPHAR25Guide to Pharmacology25UniProtKBP08913UniProt AccessionADA2A_HUMAN
synonyms:ADRA2RADRARAlpha-2 adrenergic receptor subtype C10Alpha-2A adrenoceptorAlpha-2A adrenoreceptorAlpha-2AAR
amino-acid-sequence:>lcl|BSEQ0021255|Alpha-2A adrenergic receptor MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS LNPVIYTIFNHDFRRAFKKILCRGDRKRIV
gene-sequence:>lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A) ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC ACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG CTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG GCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC GTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG TGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC GCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC ACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC TTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG CCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC TTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT CGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC ACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG GCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG CGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT CCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG GTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG GCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG CAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG TGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC ACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC TACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC AGGAAGCGGATCGTGTGA
pfams:PF000017tm_1
go-classifiers:componentbasolateral plasma membranecomponentcytoplasmcomponentintegral component of plasma membranecomponentplasma membranecomponentreceptor complexcomponentsynapsefunctionalpha-1B adrenergic receptor bindingfunctionalpha-2C adrenergic receptor bindingfunctionalpha2-adrenergic receptor activityfunctionepinephrine bindingfunctionheterotrimeric G-protein bindingfunctionnorepinephrine bindingfunctionprotein heterodimerization activityfunctionprotein homodimerization activityfunctionprotein kinase bindingfunctionthioesterase bindingprocessactin cytoskeleton organizationprocessactivation of MAPK activity by adrenergic receptor signaling pathwayprocessactivation of protein kinase activityprocessactivation of protein kinase B activityprocessacute inflammatory responseprocessadenylate cyclase-inhibiting adrenergic receptor signaling pathwayprocessblood coagulationprocesscell-cell signalingprocesscellular response to hormone stimulusprocessDNA replicationprocessenergy reserve metabolic processprocessepidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathwayprocessfear responseprocessfemale pregnancyprocessG-protein coupled receptor signaling pathwayprocessglucose homeostasisprocessintestinal absorptionprocessmovement of cell or subcellular componentprocessnegative regulation of adenylate cyclase activityprocessnegative regulation of adrenergic receptor signaling pathwayprocessnegative regulation of calcium ion transmembrane transporter activityprocessnegative regulation of calcium ion transportprocessnegative regulation of calcium ion-dependent exocytosisprocessnegative regulation of cAMP biosynthetic processprocessnegative regulation of epinephrine secretionprocessnegative regulation of insulin secretionprocessnegative regulation of insulin secretion involved in cellular response to glucose stimulusprocessnegative regulation of lipid catabolic processprocessnegative regulation of norepinephrine secretionprocessnegative regulation of uterine smooth muscle contractionprocessphospholipase C-activating adrenergic receptor signaling pathwayprocessplatelet activationprocesspositive regulation of cell migrationprocesspositive regulation of cell proliferationprocesspositive regulation of cytokine productionprocesspositive regulation of epidermal growth factor-activated receptor activityprocesspositive regulation of MAP kinase activityprocesspositive regulation of membrane protein ectodomain proteolysisprocesspositive regulation of potassium ion transportprocesspositive regulation of vasodilationprocesspositive regulation of wound healingprocessRas protein signal transductionprocessregulation of insulin secretionprocessregulation of vasoconstrictionprocessRho protein signal transductionprocesssignal transductionprocesssmall molecule metabolic processprocessthermoception
name:Alpha-2B adrenergic receptor
general-function:Epinephrine binding
specific-function:Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol.
gene-name:ADRA2B
locus:2p13-q13
cellular-location:Cell membrane
transmembrane-regions:13-38 49-69 87-107 129-149 173-193 370-393 403-423
signal-regions:
theoretical-pi:8.52
molecular-weight:49565.8
chromosome-location:2
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:282GenAtlasADRA2BGenBank Gene DatabaseM34041GenBank Protein Database178198IUPHAR26Guide to Pharmacology26UniProtKBP18089UniProt AccessionADA2B_HUMAN
synonyms:ADRA2L1ADRA2RL1Alpha-2 adrenergic receptor subtype C2Alpha-2B adrenoceptorAlpha-2B adrenoreceptorAlpha-2BAR
amino-acid-sequence:>lcl|BSEQ0010396|Alpha-2B adrenergic receptor MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADIL VATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEY NSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGS FFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASV ASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEE EEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQL TREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNP VIYTIFNQDFRRAFRRILCRPWTQTAW
gene-sequence:>lcl|BSEQ0010397|Alpha-2B adrenergic receptor (ADRA2B) ATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC TTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC CGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG GTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC CGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC GTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC AACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC GCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG CGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT TTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA CGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG CCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG GCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG ACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA GGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG GAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC TCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT GGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGACGG GCGCAGCTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT GTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGAGCCATCTGCCCGAAGCAC TGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA CTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC CTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentplasma membranefunctionalpha2-adrenergic receptor activityfunctionepinephrine bindingprocessactivation of MAPK activity by adrenergic receptor signaling pathwayprocessactivation of protein kinase B activityprocessblood coagulationprocesscell-cell signalingprocessepidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathwayprocessG-protein coupled receptor signaling pathwayprocessnegative regulation of epinephrine secretionprocessnegative regulation of norepinephrine secretionprocessplatelet activationprocesspositive regulation of neuron differentiationprocessregulation of smooth muscle contractionprocessregulation of vasoconstriction
name:Alpha-2C adrenergic receptor
general-function:Protein homodimerization activity
specific-function:Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
gene-name:ADRA2C
locus:4p16
cellular-location:Cell membrane
transmembrane-regions:52-76 89-114 125-147 169-191 208-231 380-407 421-441
signal-regions:
theoretical-pi:10.69
molecular-weight:49521.585
chromosome-location:4
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:283GenAtlasADRA2CGenBank Gene DatabaseJ03853GenBank Protein Database178194IUPHAR27Guide to Pharmacology27UniProtKBP18825UniProt AccessionADA2C_HUMAN
synonyms:ADRA2L2ADRA2RL2Alpha-2 adrenergic receptor subtype C4Alpha-2C adrenoceptorAlpha-2C adrenoreceptorAlpha-2CAR
amino-acid-sequence:>lcl|BSEQ0000681|Alpha-2C adrenergic receptor MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ
gene-sequence:>lcl|BSEQ0010255|Alpha-2C adrenergic receptor (ADRA2C) ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCC GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC GAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC GCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG TTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG CAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG CCCGGTGGCCGCCTGTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG CGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC ACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC AGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG TTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC AGGCAGTGA
pfams:PF000017tm_1
go-classifiers:componentaxon terminuscomponentcytoplasmcomponentendosomecomponentintegral component of plasma membranecomponentplasma membranefunctionalpha-2A adrenergic receptor bindingfunctionalpha2-adrenergic receptor activityfunctionepinephrine bindingfunctionprotein heterodimerization activityfunctionprotein homodimerization activityprocessactivation of MAPK activity by adrenergic receptor signaling pathwayprocessactivation of protein kinase B activityprocessadenylate cyclase-inhibiting adrenergic receptor signaling pathwayprocessblood coagulationprocesscell-cell signalingprocessenergy reserve metabolic processprocessepidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathwayprocessfemale pregnancyprocessG-protein coupled receptor signaling pathwayprocessnegative regulation of adenylate cyclase activityprocessnegative regulation of epinephrine secretionprocessnegative regulation of insulin secretion involved in cellular response to glucose stimulusprocessnegative regulation of norepinephrine secretionprocessnegative regulation of uterine smooth muscle contractionprocessplatelet activationprocesspositive regulation of neuron differentiationprocesspositive regulation of vasoconstrictionprocessregulation of insulin secretionprocessregulation of sensory perception of painprocesssmall molecule metabolic process
id:BE0000644
name:ATP-sensitive inward rectifier potassium channel 1
organism:Humans
action:inhibitor
Bkaily G, Caille JP, Payet MD, Peyrow M, Sauve R, Renaud JF, Sperelakis N: Bethanidine increases one type of potassium current and relaxes aortic muscle. Can J Physiol Pharmacol. 1988 Jun;66(6):731-6.
Bkaily G: Bethanidine, nitroprusside and atrial natriuretic factor open a cGMP-sensitive K+ channel in aortic muscle. Prog Clin Biol Res. 1990;327:507-15.
known-action:yes
name:ATP-sensitive inward rectifier potassium channel 1
general-function:Phosphatidylinositol-4,5-bisphosphate binding
specific-function:In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This channel is activated by internal ATP and can be blocked by external barium.
gene-name:KCNJ1
locus:11q24
cellular-location:Cell membrane
transmembrane-regions:78-102 156-177
signal-regions:
theoretical-pi:9.04
molecular-weight:44794.6
chromosome-location:11
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:6255GenAtlasKCNJ1GenBank Gene DatabaseU12541GenBank Protein Database529313IUPHAR429Guide to Pharmacology429UniProtKBP48048UniProt AccessionKCNJ1_HUMAN
synonyms:ATP-regulated potassium channel ROM-KInward rectifier K(+) channel Kir1.1Potassium channel, inwardly rectifying subfamily J member 1ROMK1
amino-acid-sequence:>lcl|BSEQ0001284|ATP-sensitive inward rectifier potassium channel 1 MNASSRNVFDTLIRVLTESMFKHLRKWVVTRFFGHSRQRARLVSKDGRCNIEFGNVEAQS RFIFFVDIWTTVLDLKWRYKMTIFITAFLGSWFFFGLLWYAVAYIHKDLPEFHPSANHTP CVENINGLTSAFLFSLETQVTIGYGFRCVTEQCATAIFLLIFQSILGVIINSFMCGAILA KISRPKKRAKTITFSKNAVISKRGGKLCLLIRVANLRKSLLIGSHIYGKLLKTTVTPEGE TIILDQININFVVDAGNENLFFISPLTIYHVIDHNSPFFHMAAETLLQQDFELVVFLDGT VESTSATCQVRTSYVPEEVLWGYRFAPIVSKTKEGKYRVDFHNFSKTVEVETPHCAMCLY NEKDVRARMKRGYDNPNFILSEVNETDDTKM
gene-sequence:>lcl|BSEQ0010449|ATP-sensitive inward rectifier potassium channel 1 (KCNJ1) ATGAATGCTTCCAGTCGGAATGTGTTTGACACGTTGATCAGGGTGTTGACAGAAAGTATG TTCAAACATCTTCGGAAATGGGTCGTCACTCGCTTTTTTGGGCATTCTCGGCAAAGAGCA AGGCTAGTCTCCAAAGATGGAAGGTGCAACATAGAATTTGGCAATGTGGAGGCACAGTCA AGGTTTATATTCTTTGTGGACATCTGGACAACGGTACTTGACCTCAAGTGGAGATACAAA ATGACCATTTTCATCACAGCCTTCTTGGGGAGTTGGTTTTTCTTTGGTCTCCTGTGGTAT GCAGTAGCGTACATTCACAAAGACCTCCCGGAATTCCATCCTTCTGCCAATCACACTCCC TGTGTGGAGAATATTAATGGCTTGACCTCAGCTTTTCTGTTTTCTCTGGAGACTCAAGTG ACCATTGGATATGGATTCAGGTGTGTGACAGAACAGTGTGCCACTGCCATTTTTCTGCTT ATCTTTCAGTCTATACTTGGAGTTATAATCAATTCTTTCATGTGTGGGGCCATCTTAGCC AAGATCTCCAGGCCCAAAAAACGTGCCAAGACCATTACGTTCAGCAAGAACGCAGTGATC AGCAAACGGGGAGGGAAGCTTTGCCTCCTAATCCGAGTGGCTAATCTCAGGAAGAGCCTT CTTATTGGCAGTCACATTTATGGAAAGCTTCTGAAGACCACAGTCACTCCTGAAGGAGAG ACCATTATTTTGGACCAGATCAATATCAACTTTGTAGTTGACGCTGGGAATGAAAATTTA TTCTTCATCTCCCCATTGACAATTTACCATGTCATTGATCACAACAGCCCTTTCTTCCAC ATGGCAGCGGAGACCCTTCTCCAGCAGGACTTTGAATTAGTGGTGTTTTTAGATGGCACA GTGGAGTCCACCAGTGCTACCTGCCAAGTCCGGACATCCTATGTCCCAGAGGAGGTGCTT TGGGGCTACCGTTTTGCTCCCATAGTATCCAAGACAAAGGAAGGGAAATACCGAGTGGAT TTCCATAACTTTAGCAAGACAGTGGAAGTGGAGACCCCTCACTGTGCCATGTGCCTTTAT AATGAGAAAGATGTTAGAGCCAGGATGAAGAGAGGCTATGACAACCCCAACTTCATCTTG TCAGAAGTCAATGAAACAGATGACACCAAAATGTAA
pfams:PF01007IRK
go-classifiers:componentintegral component of plasma membranecomponentplasma membranecomponentvoltage-gated potassium channel complexfunctionATP bindingfunctionATP-activated inward rectifier potassium channel activityfunctioninward rectifier potassium channel activityfunctionphosphatidylinositol-4,5-bisphosphate bindingprocesscardiovascular system developmentprocessexcretionprocesskidney developmentprocesspost-embryonic developmentprocesspotassium ion importprocesspotassium ion transportprocessregulation of G-protein activated inward rectifier potassium channel activityprocessregulation of ion transmembrane transportprocessrenal sodium ion absorptionprocesssynaptic transmissionprocesstissue homeostasis
id:BE0004872
name:Beta adrenergic receptor
organism:Humans
action:antagonist
Hart GR, Anderson RJ: Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981 Aug;141(9):1125-7.
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Bacaner MB, Benditt DG: Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias. Am J Cardiol. 1982 Oct;50(4):728-34.
known-action:unknown
name:Beta-1 adrenergic receptor
general-function:Receptor signaling protein activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
gene-name:ADRB1
locus:10q24-q26
cellular-location:Cell membrane
transmembrane-regions:56-84 94-120 133-154 173-196 223-248 320-349 355-377
signal-regions:
theoretical-pi:9.03
molecular-weight:51322.1
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:285GenAtlasADRB1GenBank Gene DatabaseJ03019GenBank Protein Database178200IUPHAR28Guide to Pharmacology28UniProtKBP08588UniProt AccessionADRB1_HUMAN
synonyms:ADRB1RB1ARBeta-1 adrenoceptorBeta-1 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0010188|Beta-1 adrenergic receptor MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV
gene-sequence:>lcl|BSEQ0010189|Beta-1 adrenergic receptor (ADRB1) ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG
pfams:PF000017tm_1
go-classifiers:componentearly endosomecomponentintegral component of plasma membranecomponentplasma membranefunctionalpha-2A adrenergic receptor bindingfunctionbeta-adrenergic receptor activityfunctionbeta1-adrenergic receptor activityfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionPDZ domain bindingfunctionprotein heterodimerization activityfunctionRas guanyl-nucleotide exchange factor activityfunctionreceptor signaling protein activityprocessactivation of adenylate cyclase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessbrown fat cell differentiationprocesscell-cell signalingprocessdiet induced thermogenesisprocessfear responseprocessheat generationprocessintracellular signal transductionprocessnegative regulation of multicellular organism growthprocesspositive regulation of cAMP biosynthetic processprocesspositive regulation of cAMP-mediated signalingprocesspositive regulation of GTPase activityprocesspositive regulation of heart rate by epinephrine-norepinephrineprocesspositive regulation of the force of heart contraction by epinephrine-norepinephrineprocessresponse to coldprocesstemperature homeostasisprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure
name:Beta-2 adrenergic receptor
general-function:Protein homodimerization activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
gene-name:ADRB2
locus:5q31-q32
cellular-location:Cell membrane
transmembrane-regions:35-58 72-95 107-129 151-174 197-220 275-298 306-329
signal-regions:
theoretical-pi:7.44
molecular-weight:46458.32
chromosome-location:5
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:286GenAtlasADRB2GenBank Gene DatabaseY00106GenBank Protein Database29371IUPHAR29Guide to Pharmacology29UniProtKBP07550UniProt AccessionADRB2_HUMAN
synonyms:ADRB2RB2ARBeta-2 adrenoceptorBeta-2 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0037061|Beta-2 adrenergic receptor MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL
gene-sequence:>lcl|BSEQ0020478|Beta-2 adrenergic receptor (ADRB2) ATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCG GACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATG TCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAG TTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG GTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACT TTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGC ATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAG TACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTG TCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAA GCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCC ATTGCCTCTTCCATCGTGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCC AGGGTCTTTCAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTC CATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGC ACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGAT AACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGT TTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTG TGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACA GGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGAC CTCCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGAT TCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAA
pfams:PF000017tm_1
go-classifiers:componentapical plasma membranecomponentaxoncomponentdendritic spinecomponentearly endosomecomponentendosomecomponentintegral component of plasma membranecomponentlysosomecomponentneuronal cell body membranecomponentnucleuscomponentplasma membranecomponentreceptor complexcomponentsarcolemmafunctionbeta2-adrenergic receptor activityfunctiondopamine bindingfunctiondrug bindingfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionpotassium channel regulator activityfunctionprotein homodimerization activityprocessactivation of adenylate cyclase activityprocessactivation of transmembrane receptor protein tyrosine kinase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessadenylate cyclase-modulating G-protein coupled receptor signaling pathwayprocessagingprocessassociative learningprocessbone resorptionprocessbrown fat cell differentiationprocesscell surface receptor signaling pathwayprocesscell-cell signalingprocesscellular response to hypoxiaprocessdesensitization of G-protein coupled receptor protein signaling pathway by arrestinprocessdiaphragm contractionprocessdiet induced thermogenesisprocessendosome to lysosome transportprocessestrous cycleprocessexcitatory postsynaptic potentialprocessfemale pregnancyprocessheat generationprocessliver regenerationprocessmitophagy in response to mitochondrial depolarizationprocessnegative regulation of angiogenesisprocessnegative regulation of inflammatory responseprocessnegative regulation of multicellular organism growthprocessnegative regulation of ossificationprocessnegative regulation of platelet aggregationprocessnegative regulation of smooth muscle contractionprocessnegative regulation of urine volumeprocesspositive regulation of apoptotic processprocesspositive regulation of ATPase activityprocesspositive regulation of autophagosome maturationprocesspositive regulation of bone mineralizationprocesspositive regulation of cell proliferationprocesspositive regulation of lipophagyprocesspositive regulation of MAPK cascadeprocesspositive regulation of potassium ion transportprocesspositive regulation of protein ubiquitinationprocesspositive regulation of skeletal muscle tissue growthprocesspositive regulation of sodium ion transportprocesspositive regulation of the force of heart contraction by epinephrineprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of vasodilationprocessreceptor-mediated endocytosisprocessregulation of calcium ion transportprocessregulation of sensory perception of painprocessresponse to coldprocessresponse to dexamethasoneprocessresponse to estrogenprocessresponse to monoamineprocessresponse to progesteroneprocessresponse to testosteroneprocesssynaptic transmission, glutamatergicprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressureprocesswound healing
name:Beta-3 adrenergic receptor
general-function:Protein homodimerization activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
gene-name:ADRB3
locus:8p12-p11.2
cellular-location:Cell membrane
transmembrane-regions:37-63 73-91 112-133 156-178 204-225 293-314 327-347
signal-regions:
theoretical-pi:9.07
molecular-weight:43518.615
chromosome-location:8
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:288GenAtlasADRB3GenBank Gene DatabaseM29932GenBank Protein Database178896IUPHAR30Guide to Pharmacology30UniProtKBP13945UniProt AccessionADRB3_HUMAN
synonyms:ADRB3RB3ARBeta-3 adrenoceptorBeta-3 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0010709|Beta-3 adrenergic receptor MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLVIV AIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSVDVLC VTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIMSQWWRV GADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVATRQLRLLRG ELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALCTLGLIMGT FTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDFRSAFRRLL CRCGRRLPPEPCAAARPALFPSGVPAARSSPAQPRLCQRLDGASWGVS
gene-sequence:>lcl|BSEQ0010710|Beta-3 adrenergic receptor (ADRB3) ATGGCTCCGTGGCCTCACGAGAACAGCTCTCTTGCCCCATGGCCGGACCTCCCCACCCTG GCGCCCAATACCGCCAACACCAGTGGGCTGCCAGGGGTTCCGTGGGAGGCGGCCCTAGCC GGGGCCCTGCTGGCGCTGGCGGTGCTGGCCACCGTGGGAGGCAACCTGCTGGTCATCGTG GCCATCGCCTGGACTCCGAGACTCCAGACCATGACCAACGTGTTCGTGACTTCGCTGGCC GCAGCCGACCTGGTGATGGGACTCCTGGTGGTGCCGCCGGCGGCCACCTTGGCGCTGACT GGCCACTGGCCGTTGGGCGCCACTGGCTGCGAGCTGTGGACCTCGGTGGACGTGCTGTGT GTGACCGCCAGCATCGAAACCCTGTGCGCCCTGGCCGTGGACCGCTACCTGGCTGTGACC AACCCGCTGCGTTACGGCGCACTGGTCACCAAGCGCTGCGCCCGGACAGCTGTGGTCCTG GTGTGGGTCGTGTCGGCCGCGGTGTCGTTTGCGCCCATCATGAGCCAGTGGTGGCGCGTA GGGGCCGACGCCGAGGCGCAGCGCTGCCACTCCAACCCGCGCTGCTGTGCCTTCGCCTCC AACATGCCCTACGTGCTGCTGTCCTCCTCCGTCTCCTTCTACCTTCCTCTTCTCGTGATG CTCTTCGTCTACGCGCGGGTTTTCGTGGTGGCTACGCGCCAGCTGCGCTTGCTGCGCGGG GAGCTGGGCCGCTTTCCGCCCGAGGAGTCTCCGCCGGCGCCGTCGCGCTCTCTGGCCCCG GCCCCGGTGGGGACGTGCGCTCCGCCCGAAGGGGTGCCCGCCTGCGGCCGGCGGCCCGCG CGCCTCCTGCCTCTCCGGGAACACCGGGCCCTGTGCACCTTGGGTCTCATCATGGGCACC TTCACTCTCTGCTGGTTGCCCTTCTTTCTGGCCAACGTGCTGCGCGCCCTGGGGGGCCCC TCTCTAGTCCCGGGCCCGGCTTTCCTTGCCCTGAACTGGCTAGGTTATGCCAATTCTGCC TTCAACCCGCTCATCTACTGCCGCAGCCCGGACTTTCGCAGCGCCTTCCGCCGTCTTCTG TGCCGCTGCGGCCGTCGCCTGCCTCCGGAGCCCTGCGCCGCCGCCCGCCCGGCCCTCTTC CCCTCGGGCGTTCCTGCGGCCCGGAGCAGCCCAGCGCAGCCCAGGCTTTGCCAACGGCTC GACGGGGCTTCTTGGGGAGTTTCTTAG
pfams:PF000017tm_1
go-classifiers:componentintegral component of plasma membranecomponentnucleuscomponentplasma membranecomponentreceptor complexfunctionbeta-adrenergic receptor activityfunctionbeta3-adrenergic receptor activityfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionprotein homodimerization activityprocessactivation of adenylate cyclase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessadenylate cyclase-modulating G-protein coupled receptor signaling pathwayprocessagingprocessbrown fat cell differentiationprocesscarbohydrate metabolic processprocesscell-cell signalingprocessdiet induced thermogenesisprocesseating behaviorprocessenergy reserve metabolic processprocessG-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerprocessgeneration of precursor metabolites and energyprocessheat generationprocessnegative regulation of multicellular organism growthprocesspositive regulation of MAPK cascadeprocessresponse to antibioticprocessresponse to coldprocesstemperature homeostasisprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure

酶

载体

运输工具

药物反应

效应

不良反应